Exact Mass: 498.2114
Exact Mass Matches: 498.2114
Found 286 metabolites which its exact mass value is equals to given mass value 498.2114
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Conivaptan
Conivaptan is only found in individuals that have used or taken this drug. It is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).Conivaptan is a dual AVP antagonist with nanomolar affinity for human arginine vasopressin V1A and V2 receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water. C - Cardiovascular system > C03 - Diuretics > C03X - Other diuretics > C03XA - Vasopressin antagonists C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
N2-Maltulosylarginine
N2-Maltulosylarginine is found in tea. N2-Maltulosylarginine is a constituent of Korean red ginseng. Constituent of Korean red ginseng. N2-Maltulosylarginine is found in tea.
Apitolisib
Masitinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, PDB, Protein Data Bank C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
punaglandin 4
Val Glu His Asp
Ala Asp Phe Phe
Ala Phe Asp Phe
Ala Phe Phe Asp
Cys Ile Thr Tyr
Cys Ile Tyr Thr
Cys Leu Thr Tyr
Cys Leu Tyr Thr
Cys Thr Ile Tyr
Cys Thr Leu Tyr
Cys Thr Tyr Ile
Cys Thr Tyr Leu
Cys Tyr Ile Thr
Cys Tyr Leu Thr
Cys Tyr Thr Ile
Cys Tyr Thr Leu
Asp Ala Phe Phe
Asp Asp His Ile
Asp Asp His Leu
Asp Asp Ile His
Asp Asp Leu His
Asp Glu His Val
Asp Glu Val His
Asp Phe Ala Phe
Asp Phe Phe Ala
Asp His Asp Ile
Asp His Asp Leu
Asp His Glu Val
Asp His Ile Asp
Asp His Leu Asp
Asp His Val Glu
Asp Ile Asp His
Asp Ile His Asp
Asp Leu Asp His
Asp Leu His Asp
Asp Val Glu His
Asp Val His Glu
Glu Asp His Val
Glu Asp Val His
Glu Phe Phe Gly
Glu Phe Gly Phe
Glu Gly Phe Phe
Glu His Asp Val
Glu His Val Asp
Glu Val Asp His
Glu Val His Asp
Phe Ala Asp Phe
Phe Ala Phe Asp
Phe Asp Ala Phe
Phe Asp Phe Ala
Phe Glu Phe Gly
Phe Glu Gly Phe
Phe Phe Ala Asp
Phe Phe Asp Ala
Phe Phe Glu Gly
Phe Phe Gly Glu
Phe Gly Glu Phe
Phe Gly Phe Glu
Phe Met Thr Thr
Phe Thr Met Thr
Phe Thr Thr Met
Gly Glu Phe Phe
Gly Phe Glu Phe
Gly Phe Phe Glu
Gly Pro Tyr Tyr
Gly Tyr Pro Tyr
Gly Tyr Tyr Pro
His Asp Asp Ile
His Asp Asp Leu
His Asp Glu Val
His Asp Ile Asp
His Asp Leu Asp
His Asp Val Glu
His Glu Asp Val
His Glu Val Asp
His Ile Asp Asp
His Leu Asp Asp
His Asn Gln Thr
His Asn Thr Gln
His Gln Asn Thr
His Gln Gln Ser
His Gln Ser Gln
His Gln Thr Asn
His Ser Gln Gln
His Thr Asn Gln
His Thr Gln Asn
His Val Asp Glu
His Val Glu Asp
Ile Cys Thr Tyr
Ile Cys Tyr Thr
Ile Asp Asp His
Ile Asp His Asp
Ile His Asp Asp
Ile Thr Cys Tyr
Ile Thr Tyr Cys
Ile Tyr Cys Thr
Ile Tyr Thr Cys
Leu Cys Thr Tyr
Leu Cys Tyr Thr
Leu Asp Asp His
Leu Asp His Asp
Leu His Asp Asp
Leu Thr Cys Tyr
Leu Thr Tyr Cys
Leu Tyr Cys Thr
Leu Tyr Thr Cys
Met Phe Thr Thr
Met Ser Val Tyr
Met Ser Tyr Val
Met Thr Phe Thr
Met Thr Thr Phe
Met Val Ser Tyr
Met Val Tyr Ser
Met Tyr Ser Val
Met Tyr Val Ser
Asn His Gln Thr
Asn His Thr Gln
Asn Gln His Thr
Asn Gln Thr His
Asn Thr His Gln
Asn Thr Gln His
Pro Gly Tyr Tyr
Pro Tyr Gly Tyr
Pro Tyr Tyr Gly
Gln His Asn Thr
Gln His Gln Ser
Gln His Ser Gln
Gln His Thr Asn
Gln Asn His Thr
Gln Asn Thr His
Gln Gln His Ser
Gln Gln Ser His
Gln Ser His Gln
Gln Ser Gln His
Gln Thr His Asn
Gln Thr Asn His
Ser His Gln Gln
Ser Met Val Tyr
Ser Met Tyr Val
Ser Gln His Gln
Ser Gln Gln His
Ser Val Met Tyr
Ser Val Tyr Met
Ser Tyr Met Val
Ser Tyr Val Met
Thr Cys Ile Tyr
Thr Cys Leu Tyr
Thr Cys Tyr Ile
Thr Cys Tyr Leu
Thr Phe Met Thr
Thr Phe Thr Met
Thr His Asn Gln
Thr His Gln Asn
Thr Ile Cys Tyr
Thr Ile Tyr Cys
Thr Leu Cys Tyr
Thr Leu Tyr Cys
Thr Met Phe Thr
Thr Met Thr Phe
Thr Asn His Gln
Thr Asn Gln His
Thr Gln His Asn
Thr Gln Asn His
Thr Thr Phe Met
Thr Thr Met Phe
Thr Tyr Cys Ile
Thr Tyr Cys Leu
Thr Tyr Ile Cys
Thr Tyr Leu Cys
Val Asp Glu His
Val Asp His Glu
Val Glu Asp His
Val His Asp Glu
Val His Glu Asp
Val Met Ser Tyr
Val Met Tyr Ser
Val Ser Met Tyr
Val Ser Tyr Met
Val Tyr Met Ser
Val Tyr Ser Met
Tyr Cys Ile Thr
Tyr Cys Leu Thr
Tyr Cys Thr Ile
Tyr Cys Thr Leu
Tyr Gly Pro Tyr
Tyr Gly Tyr Pro
Tyr Ile Cys Thr
Tyr Ile Thr Cys
Tyr Leu Cys Thr
Tyr Leu Thr Cys
Tyr Met Ser Val
Tyr Met Val Ser
Tyr Pro Gly Tyr
Tyr Pro Tyr Gly
Tyr Ser Met Val
Tyr Ser Val Met
Tyr Thr Cys Ile
Tyr Thr Cys Leu
Tyr Thr Ile Cys
Tyr Thr Leu Cys
Tyr Val Met Ser
Tyr Val Ser Met
Tyr Tyr Gly Pro
Tyr Tyr Pro Gly
7Z-punaglandin 4
punaglandin 5
Conivaptan
C - Cardiovascular system > C03 - Diuretics > C03X - Other diuretics > C03XA - Vasopressin antagonists C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
UK II
punaglandin 4
punaglandin 5
N-(2-Diethylaminoethyl)-α,2-dimethyl-1,3-benzodioxole-2-acetamide
Apitolisib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a?Ki?of 17 nM for mTOR. Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a?Ki?of 17 nM for mTOR.
Olorofim
D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent
Sotrastaurin acetate
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
Masitinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, PDB, Protein Data Bank C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
validamycin A(1+)
An ammonium ion resulting from the protonation of the amino group of validamycin A. The major species at pH 7.3.
2-[5-(2-fluorophenyl)-2-tetrazolyl]-N-[2-oxo-2-[(phenylmethyl)amino]ethyl]-N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
(1R)-2-acetyl-N-(2,4-difluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
2-[(3S,6aR,8S,10aR)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3S,6aR,8R,10aR)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3R,6aR,8S,10aR)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3R,6aS,8S,10aS)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3S,6aS,8S,10aS)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3S,6aS,8R,10aS)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
2-[(3R,6aR,8R,10aR)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3R,6aS,8R,10aS)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
(1S)-2-acetyl-N-(2,4-difluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
4-[[4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino]-N-(4-pyrrolidin-1-ylpiperidin-1-yl)benzamide
1-[4-[[2-(2-Amino-5-pyrimidinyl)-7-methyl-4-(4-morpholinyl)-6-thieno[3,2-d]pyrimidinyl]methyl]-1-piperazinyl]-2-hydroxy-1-propanone
(1s,2s,3s,4s,7s,8z,11r,12s,13r,16r,17s)-2-(acetyloxy)-3,4,12,16,17-pentahydroxy-4,9,13,17-tetramethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadeca-8,14-dien-11-yl acetate
methyl (5s,6s)-5,6-bis(acetyloxy)-7-[(1e,2r)-4-chloro-2-hydroxy-2-(oct-2-en-1-yl)-5-oxocyclopent-3-en-1-ylidene]heptanoate
Argininyl-fructosyl-glucose
{"Ingredient_id": "HBIN016722","Ingredient_name": "Argininyl-fructosyl-glucose","Alias": "argininyl-fructosyl-glucose","Ingredient_formula": "C18H34N4O12","Ingredient_Smile": "C1C(C(C(C(O1)(CNC(CCCN=C(N)N)C(=O)O)O)O)OC2C(C(C(C(O2)CO)O)O)O)O","Ingredient_weight": "498.56","OB_score": "0.740573214","CAS_id": "NA","SymMap_id": "SMIT01073","TCMID_id": "1674","TCMSP_id": "MOL005311","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}